Gliosarcoma
MONDO:0016681A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).
Also known as: glioblastoma with a sarcomatous component, gliosarcoma, sarcomatous glioblastoma
2946 clinical trials for this condition and its sub-types, 65 tagged with Gliosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for aggressive brain cancer? early trial of ERAS-801 begins
Disease control Recruiting nowThis early-phase trial tests the safety of a drug called ERAS-801 in 10 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug targets a protein called EGFR that is overactive in many of these tumors. Researchers will also check if the drug affects tumor activi…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to tackle aggressive brain tumors that have come back
Disease control Recruiting nowThis early-phase study tests a new two-drug combination for adults whose high-grade glioma (a fast-growing brain tumor) has returned after standard treatment. The drugs are temozolomide (a chemotherapy pill given daily at low doses) and abexinostat (an experimental drug that may …
Phase 1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Gene-Edited stem cells may let doctors use stronger chemo against brain cancer
Disease control Recruiting nowThis study tests a new approach for people with a recently removed glioblastoma (a fast-growing brain tumor). Doctors take some of the patient's own blood stem cells, add a protective gene (P140K MGMT) to them, and return them to the patient. This allows the use of higher doses o…
Phase 2 • Sponsor: Leland Metheny • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo attack on brain cancer: early trial launches
Disease control Recruiting nowThis early-phase trial tests two experimental drugs, ABBV-637 and ABBV-155, alone or together with ERAS-801 in people whose glioblastoma has come back after standard treatment. About 60 adults with a specific genetic marker (EGFR amplification) will take part. The main goal is to…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Killer virus turned against childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Genetically modified immune cells take on deadly brain tumors
Disease control Recruiting nowThis early-stage trial tests genetically engineered natural killer (NK) cells in 25 people with recurrent glioblastoma, an aggressive brain cancer. The cells are designed to resist the tumor's defenses. The main goal is to find a safe dose and check for side effects, while also w…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Supercharged immune cells take on deadly brain tumors
Disease control Recruiting nowThis early-stage trial tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. Researchers will give patients specially engineered natural killer (NK) cells, either directly into the brain or through an …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Brain cancer hope: new drugs tested in major trial
Disease control Recruiting nowThis Phase 2 trial is testing several experimental drugs, alone or in combination, for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 460 participants will receive one of the study drugs or standard therapy. The main goal is to see if these new treatm…
Phase 2 • Sponsor: David Reardon, MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Second radiation blast targets recurrent brain tumors
Disease control Recruiting nowThis early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, with different schedules to find the safest dose. The goal is to …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control Recruiting nowThis trial tests a new approach for glioblastoma, an aggressive brain cancer. A device implanted in the skull uses ultrasound to temporarily open the blood-brain barrier, allowing immune-boosting drugs to reach the tumor. The study involves 25 adults who have completed radiation,…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
Disease control Recruiting nowThis pilot trial is testing whether an advanced MRI technique called spectroscopic MRI (sMRI) can uncover hidden areas of recurrent glioblastoma that standard scans miss. Using that information, doctors will deliver a higher dose of proton radiation directly to the tumor, along w…
Sponsor: University of Miami • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cold virus hijacked to attack returning brain tumors in early trial
Disease control Recruiting nowThis early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a daily pastille help fight recurrent brain tumors?
Disease control Recruiting nowThis pilot study tests whether adding APG-157 (a pastille dissolved in the mouth) to standard bevacizumab can help people with recurrent high-grade glioma. About 30 participants will take APG-157 three times daily while continuing bevacizumab. The study tracks survival, tumor res…
Phase 1/2 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Ultrasound opens brain barrier to supercharge immune attack on deadly tumor
Disease control Recruiting nowThis early-stage trial tests a new treatment for a fast-growing brain cancer called glioblastoma. It combines special immune cells (EGFR BATs) with low-intensity focused ultrasound to temporarily open the blood-brain barrier, allowing more treatment to reach the tumor. The study …
Phase 1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immune cells injected into brain show promise against deadly cancer
Disease control Recruiting nowThis early-phase study tests a new treatment for people with a recurring type of brain cancer called glioblastoma. The treatment uses specially designed immune cells (NK-92/5.28.z) that are injected directly into the brain to attack cancer cells. The main goals are to check safet…
Phase 1 • Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a Pre-Surgery immune booster tame brain cancer?
Disease control Recruiting nowThis early-phase trial is testing whether giving the immunotherapy drug ipilimumab before standard surgery and chemoradiation is safe and helpful for people with newly diagnosed glioblastoma, an aggressive brain cancer. Sixteen participants will receive up to two doses of ipilimu…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug aims to boost immune attack on aggressive brain tumors
Disease control Recruiting nowThis phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells i…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental virus and immunotherapy combo takes on deadly brain tumors
Disease control Recruiting nowThis early-phase trial is testing a combination of two treatments for people with recurrent or newly diagnosed glioblastoma and other aggressive brain cancers. The first treatment is pembrolizumab, an immunotherapy that helps the immune system attack cancer cells. The second is M…
Phase 1/2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo aims to boost immune attack on returning brain tumors
Disease control Recruiting nowThis study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The goal is to see if this combination can help the immune system fight the tumor and improve survival. About…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Brain tumor cocktail: could a 4-Drug combo tame glioblastoma?
Disease control Recruiting nowThis early-stage trial is testing whether combining a chemotherapy wafer placed in the brain during surgery with an immunotherapy drug and standard radiation (with or without another chemo pill) is safe and feasible for people with newly-diagnosed glioblastoma. About 50 adults wh…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a smell test forecast brain tumor survival?
Knowledge-focused Recruiting nowThis study investigates whether a simple smell test could help predict survival and cognitive decline in adults newly diagnosed with glioblastoma, an aggressive brain cancer. Researchers will measure olfactory function at several points during treatment and compare it with surviv…
Sponsor: Sied Kebir • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Brain tumor tissue bank could pave way for future therapies
Knowledge-focused Recruiting nowThis study collects and preserves glioblastoma tissue from 120 patients during standard surgery, along with blood samples. Researchers will analyze tissue from different tumor regions to understand its structure and genetics. The goal is to learn more about how glioblastoma works…
Sponsor: Baptist Health South Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC